116 related articles for article (PubMed ID: 15477874)
1. MUC1 expression in human prostate cancer cell lines and primary tumors.
O'Connor JC; Julian J; Lim SD; Carson DD
Prostate Cancer Prostatic Dis; 2005; 8(1):36-44. PubMed ID: 15477874
[TBL] [Abstract][Full Text] [Related]
2. Synergistic stimulation of MUC1 expression in normal breast epithelia and breast cancer cells by interferon-gamma and tumor necrosis factor-alpha.
Lagow EL; Carson DD
J Cell Biochem; 2002; 86(4):759-72. PubMed ID: 12210742
[TBL] [Abstract][Full Text] [Related]
3. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.
Burke PA; Gregg JP; Bakhtiar B; Beckett LA; Denardo GL; Albrecht H; De Vere White RW; De Nardo SJ
Int J Oncol; 2006 Jul; 29(1):49-55. PubMed ID: 16773184
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical staining of mucin 1 in prostate tissues.
Rabiau N; Dechelotte P; Guy L; Satih S; Bosviel R; Fontana L; Kemeny JL; Boiteux JP; Bignon YJ; Bernard-Gallon D
In Vivo; 2009; 23(2):203-7. PubMed ID: 19414404
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas.
Singh AP; Chauhan SC; Bafna S; Johansson SL; Smith LM; Moniaux N; Lin MF; Batra SK
Prostate; 2006 Mar; 66(4):421-9. PubMed ID: 16302265
[TBL] [Abstract][Full Text] [Related]
6. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.
Lu Y; Wang J; Xu Y; Koch AE; Cai Z; Chen X; Galson DL; Taichman RS; Zhang J
Mol Cancer Res; 2008 Apr; 6(4):546-54. PubMed ID: 18344492
[TBL] [Abstract][Full Text] [Related]
7. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer.
Papadopoulos I; Sivridis E; Giatromanolaki A; Koukourakis MI
Clin Cancer Res; 2001 Jun; 7(6):1533-8. PubMed ID: 11410487
[TBL] [Abstract][Full Text] [Related]
8. CCR2 expression correlates with prostate cancer progression.
Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
[TBL] [Abstract][Full Text] [Related]
9. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
10. MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage.
Kirschenbaum A; Itzkowitz SH; Wang JP; Yao S; Eliashvili M; Levine AC
Mol Urol; 1999; 3(3):163-168. PubMed ID: 10851319
[TBL] [Abstract][Full Text] [Related]
11. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.
Maria McCrohan A; Morrissey C; O'Keane C; Mulligan N; Watson C; Smith J; Fitzpatrick JM; Watson RW
Cancer; 2006 Jun; 106(12):2743-52. PubMed ID: 16703599
[TBL] [Abstract][Full Text] [Related]
12. [Expression and clinical significance of antiapoptosis gene XIAP in prostate cancer].
Liu J; Li M; Xia S
Zhonghua Nan Ke Xue; 2004 Nov; 10(11):832-5. PubMed ID: 15595685
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
Heer R; Douglas D; Mathers ME; Robson CN; Leung HY
J Pathol; 2004 Dec; 204(5):578-86. PubMed ID: 15538740
[TBL] [Abstract][Full Text] [Related]
14. [Tumor infiltrating dendritic cells and Mucin1 gene expression in benign prostatic hyperplasia and prostate cancer].
Xiang ST; Zhou SW; Guan W; Wang QZ; Zhang B; Liu JH; Ye ZQ
Zhonghua Nan Ke Xue; 2003 Oct; 9(7):497-500. PubMed ID: 14628595
[TBL] [Abstract][Full Text] [Related]
15. Regulation of interleukin-8 expression in human prostate cancer cells by insulin-like growth factor-I and inflammatory cytokines.
Kooijman R; Himpe E; Potikanond S; Coppens A
Growth Horm IGF Res; 2007 Oct; 17(5):383-91. PubMed ID: 17513150
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
17. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
18. Expression and nuclear localization of ErbB3 in prostate cancer.
Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
[TBL] [Abstract][Full Text] [Related]
19. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
20. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
